Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 16Cholangiocarcinoma 3Carcinoma, Renal Cell 3Biliary Tract Neoplasms 3Uterine Cervical Neoplasms 2Stomach Neoplasms 2Liver Neoplasms 2Advanced Endometrial Cancer 2Thyroid Neoplasms 1Solid Tumors 1Recurrence 1Neoplasm Metastasis 1Hepatitis B 1Esophageal Squamous Cell Carcinoma 1Diabetes Mellitus, Insulin-Dependent, 12 1Clear-cell metastatic renal cell carcinoma 1Cirrhosis, Familial, with Pulmonary Hypertension 1Breast Neoplasms 1BTC 1Advanced Triple Negative Breast Cancer 1Advanced Non-squamous Non-small-cell Lung Cancer 1Advanced Hepatocellular Carcinoma (HCC) 1Adenocarcinoma 1

Interventions

pembrolizumab 1lenvatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Advanced Hepatocellular Carcinoma (HCC) × lenvatinib × Clear all
NCT07282509 2025-12-15

Safety and Efficacy of Paclitaxel Liposome Arterial Infusion Combined With Systemic Therapy for Second-Line Treatment of Advanced Liver Cancer

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Phase 1/2 Not yet recruiting
116 enrolled
Gastrointestinal

Advanced Hepatocellular Carcinoma (HCC)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡